amaxa GmbH-Promega Corporation Partnership to Enable Simplified Monitoring of Cell Signaling Events in Stem Cells, Cancer Cells and Primary Cells

COLOGNE, Germany & MADISON, Wis.--(BUSINESS WIRE)--Amaxa and Promega today announced an agreement to develop applications that will provide cell biologists broader access to monitor cell signaling events in difficult-to-transfect cells, including stem cells, cancer cells and primary cells. Integrating their industry leading technologies in luminescence-based assays and transfection methodologies will simplify transfection of reporter genes and assay development in these difficult-to-transfect cell types.

Back to news